ClinicalTrials.gg
RecruitingNCT07394153PACRIMYELUpdated Oct 2, 2026

Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia

A Phase 2 interventional study of Pacritinib in Myelofibrosis,MF, sponsored by Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas. Recruiting at 13 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 2, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing pacritinib in Primary Myelofibrosis — 6 open to participants now, 8 under way, 1 of them phase 3. pacritinib · Primary Myelofibrosis.

Planned enrollment
10th of 18
30 · median 35
Started
2026
with 2 others
Phase 2
8 of 18
4 open now
Registered
16th of 18
by date
Lead sponsor
1 of 18
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas

Among the 18 studies testing pacritinib in Primary Myelofibrosis, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is one of 8 in phase 2, and was the 16th registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

6 of the 18 studies testing pacritinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About pacritinib

pacritinib: first FDA approval 2022 (VONJO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing pacritinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

We hypothesize that pacritinib leads to modification of the myelofibrosis (MF) disease phenotype, especially related to BM fibrosis and cytopenias; due potentially to its dual effect as an inhibitor of the JAK and NFκB pathways, through its targets JAK2 and IRAK1 respectively, leading to a decrease of inflammatory cytokines and/or effects on stem/progenitor populations restoring hematopoiesis New evidence suggests that blocking simultaneously the JAK/STAT and NF-κB pathways might have a beneficial effect on aspects that only inhibition of the JAK pathway cannot achieve: partial recovery of BM histology and

PACRIMYEL is a multicenter, open-label, single arm, phase II, exploratory study including patients with MF and platelet count between 50 - 120 x 109/L. Clinic visits will occur on weeks 4, 8, 12, 24, 36 and 52 during the first year and every 12 weeks during the second year of the treatment, and pacritinib will be dispensed at every visit to the clinic.

Bone fibrosis will be assessed by biopsy and MRI imaging [mDixon Quant "(Philips), IDEAL IQ (General Electric) or qDixon (Siemens)] on weeks 24 and 52 after the first dose of study treatment. Splenomegaly and SVR (Splenic Volume Reduction) will be assessed by physical exam and MRI imaging on weeks 24 and 52 after the first dose of study treatment if splenomegaly at diagnosis. Same MRI to evaluate BM imaging will be used to measure spleen volume. Additionally, spleen size will be assessed by physical exam during the routine clinic visits. All patients should complete all efficacy assessments through Week 52, including patients who stop study treatment or have protocol-defined progressive disease prior to Week 24 and 52, unless the patient withdraws consent or dies. For patients who discontinue treatment before disease assessments on week 24 and week 52 for other reasons different than protocol-based progression of the disease (i.e. toxicity), and with no recent disease / fibrosis assessment (last BM biopsy > 12 weeks), disease and fibrosis assessments will be performed by the end of treatment visit. The trial includes the assessment of safety (AEs, comorbidities) throughout the study period at every visit.

Patient-reported symptoms through MPN-SAF TSS 2.0 will be collected screening, baseline (C1D1), and on Week 12, Week 24, Week 36, Week 52 and in 12-weeks intervals during the second year. Blood samples for translational research will be collected at screening and at week 24 for determination of cytokines.

03

Conditions studied

  • Myelofibrosis,MF

Browse trials for

Keywords

  • Myelofibrosis
  • JAK2 inhibitor
  • FTL3 inhibitor
  • pacritinib
  • low platelet count
  • IRAK1 inhibitor
  • Philadelphia Chromosome-negative Chronic Myeloproliferative Neoplasms
  • Bone fibrosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written and voluntary .
  2. Age ≥18 years
  3. Patients with a confirmed diagnosis of myelofibrosis, either primary myelofibrosis (PMF) or post polycythemia vera (PPV-MF) or post essential thrombocythemia (PET-MF).
  4. Patients with thrombocytopenia, delimited by counts between 50 - 120 x 109/L.
  5. Patients who require JAK-2 inhibitor therapy in the opinion of the investigator and are eligible to start treatment with pacritinib either in the (JAK2 inhibitor-naive) or in second line setting (after no response or loss of response or intolerance to one prior JAK2 inhibitor ).

    Note: patients should have recovered to grade ≤ 1 from any toxicity from previous treatment.

  6. Have a Performance Status (ECOG-PS) of 0 - 2.
  7. Have a dynamic international prognostic scoring system (DIPSS) Intermediate-1, Intermediate-2, or High risk.
  8. Peripheral blasts count \< 5% and (ANC) of ≥500/μL.
  9. Adequate liver and renal function, defined by:

    1. liver transaminases, including (ALT or GOT) and aspartate aminotransferase (AST or GOT) ≤ 3 x upper limit normal (). AST/ALT ≤5 × ULN if transaminase elevation is related to MF.
    2. Total and/or direct bilirubin ≤ 4 x ULN.
    3. Estimated (eGFR) > 30 mL/min.
  10. Adequate coagulation defined by /international normalized ratio and partial thromboplastin time ≤ 1.5 × ULN.
  11. If fertile, willing to use effective methods during the study and up to 30 days after the last dose of pacritinib.
  12. Willing to undergo and able to tolerate frequent MRI during the study and BM
  13. Able to understand and willing to complete symptom assessments.

Exclusion criteria

Exclusion Criteria:

  1. \<6 months.
  2. Splenic irradiation within the last 6 months.
  3. Previously treated with pacritinib.
  4. Concurrent enrollment in another interventional trial.
  5. Treatment with an experimental therapy within 28 days prior to the first dose of study treatment.
  6. Systemic treatment with a strong inhibitor or inducer and the treatment cannot be either discontinued or switched to a different medication within 5 half-lifes prior to study entry.
  7. Severe ( C) liver impairment.
  8. Significant recent bleeding history defined as grade ≥2 within 3 months prior to first dose of study treatment, or with active bleeding, unless precipitated by an inciting event (e.g., surgery, trauma, or injury).
  9. Conditions or medications that increase the risk of bleeding, except for aspirin (dosages of ≤100 mg per day). Patients treated with "direct-acting oral anticoagulants (DOACs), could be considered for inclusion (may be consulted with the Sponsor, GEMFIN).
  10. Any history of CTCAE grade ≥2 dysrhythmias or non-dysrhythmia cardiac conditions within 6 months prior to the first dose of study treatment. Patients with non-dysrhythmia or non- grade 2 cardiovascular conditions , may be considered for inclusion, if stable , asymptomatic and unlikely to affect patient safety.
  11. QT corrected by the Fridericia method (QTcF) prolongation >480 ms or other factors that increase the risk for QTcF interval prolongation (e.g., heart failure, hypokalemia or history of long QT interval syndrome).
  12. Class II, III, or IV congestive heart failure.
  13. Active or uncontrolled inflammatory or chronic functional bowel disorder such as Crohn's disease, inflammatory bowel disease, chronic diarrhea or constipation
  14. Other within 3 years prior to treatment Day 1, other than curatively treated basal cell or squamous cell skin or corneal cancer; curatively treated carcinoma in situ of the cervix. The exception is if patients have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy.
  15. Known seropositivity for . Known active , or C virus infection.
  16. Women who are pregnant or lactating
  17. Uncontrolled intercurrent illness, including, but not limited to, ongoing active infection, psychiatric illness, or social situation that, in the judgment of the treating physician, would limit compliance with study requirements.
  18. Any active GI or metabolic condition that could interfere with absorption of oral medication.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    PACRIMYEL

    Pacritinib administed 200 mg twice a day (BID)

    Drug: Pacritinib

Interventions

  • All patients enrolled will receive pacritinib 200 mg twice a day (BID). The maximum daily dose will be 400 mg of pacritinib. Pacritinib dose may be reduced by one level to 100 mg BID (200 mg total daily dose), or by two levels to 100 mg once daily (QD) for management of AEs. The treatment will be continued until progressive disease, unacceptable toxic effects, the patient no longer derives benefit from treatment, patients consent withdrawal or death, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Decrease in reticulin fibrosis in bone marrow (BM)

    Measured in BM biopsy. Percentage of patients who experience a decrease of ≥1 grade in reticulin fibrosis from baseline to week 52. Definition of BM fibrosis grade will follow the European consensus that ranges from 0 (scattered, less fibrotic) to 3 (difuse and dense reticulin, more fibrotic). Patients will be classified as improvement (fibrosis decrease ≥1 grade), no change, or worsening (fibrosis increase \> 1 grade).

    Time frame: from baseline to week 52 after first dose of study treatment

Secondary outcomes

  1. Improvement in BM fat fraction (FF)

    measured by quantitative quantitative Dixon Quant MRI or equivalent. Changes in the bone marrow associated with MF, such as replacement of the bone marrow fat by fibrosis or elevated numbers of hematopoietic cells, reduce the abundance of fat. Here we will report the percentage of patient who had an improvement in the FF (increase from baseline at week 52).

    Time frame: from baseline to week 52 after first dose of study treatment

  2. red blood cell (RBC) transfusion independence

    Percentage of patients who achieved no need of RBC transfusions during at least 12 week. RBC transfusion independence will be reported in subgroup of patients with the changes in the Bone Marrow (by MRI and/or BM biopsy) over the first 24 and 52 weeks of treatment.

    Time frame: from baseline to week 24 and week 52 after first dose of study treatment

  3. Improvement in hemoglobin level

    Percentage of patients who improve their hemoglobin levels without transfusion. Improvement was defined as a ≥ 1.5 g/dL increase in hemoglobin from baseline. Changes in hemoglobin level without transfusion will be reported in subgroup of patients with the changes in the Bone Marrow (by MRI and/or BM biopsy) over the first 24 and 52 weeks of treatment.

    Time frame: from baseline to week 24 and week 52 after first dose of study treatment

  4. Improvement in platelet counts

    increase of platelet count (without transfusions) in comparison to baseline of above 75 x 109/L (if platelet count was between 50 - 75 109/L at baseline) or above 100 x 109/L (if platelet count was between 75 - 100 x 109/L at baseline). Alternatively, the proportion of patients who increase platelet counts ≥25% above baseline will be measured.

    Time frame: from baseline to week 24 and week 52 after first dose of study treatment

  5. Myeloproliferative neoplasms (MPN) driver-gen Variant Allele Frequency (VAF)

    JAK2, CALR, and MPL genes are drivers of myelofibrosis. Their VAF could be quantified in peripheral blood or bone marrow and its circulating levels are usually correlated with the course of the disease. We aim to find the percentage of patients who reduced their VAF at week 24 and 52.

    Time frame: Baseline and at Week 24 and Week 52 after the first dose of study treatment

  6. Cummulative dose

    the sum of all doses of pacritinib taken from the start of study treatment, taken into consideration interruptions and reductions.

    Time frame: Throughout the study period, up to approximately 2 years

  7. Actual dose of pacritinib

    defined as the real average daily dose administered. For its calculation, the cumulative dose will be divided by the duration of the treatment, considering also the interruption periods.

    Time frame: Throughout the study period, up to approximately 2 years

  8. Relative dose intensity of pacritinib

    Defined as the percentage of the planned dose that has been actually administered. Calculated dividing actual dose by planned dose per day.

    Time frame: Throughout the study period, up to approximately 2 years

  9. Frequency of treatment-related adverse events

    number of patients who experience a treatment-related adverse event. Events will be classified and graded according to National Cancer Institute (NCI) Common Terminology Criteria (CTCAE) version 5.0

    Time frame: Throughout the study period, up to approximately 2 years

07

Study locations

12 of 13 sites recruiting
  • Hospital del Mar Barcelona
    Barcelona, Barcelona 08003, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Hospital Universitario Vall d´Hebron
    Barcelona, Barcelona 08035, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Hospital Clinic de Barcelona
    Barcelona, Barcelona 08036, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Hospital Universitario de Jerez
    Jerez de la Frontera, Cádiz 11407, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Hospital General Universitario Gregorio Marañon
    Madrid, Madrid 28007, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Hospital Universitario Ramon y Cajal
    Madrid, Madrid 28034, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Fundación Jimenez Díaz
    Madrid, Madrid 28040, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Hospital Universitario 12 de Octubre
    Madrid, Madrid 28041, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Hospital General Universitario Morales Meseguer
    Murcia, Murcia 30008, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Hospital Universitario de Salamanca
    Salamanca, Salamanca 37007, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Hospital Clínico Universitario Valencia
    Valencia, Valencia 46010, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Hospital General Universitario de Valencia
    Valencia, Valencia 46014, Spain
    Recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
  • Hospital Universitario Doctor Peset
    Valencia, Valencia 46017, Spain
    Not yet recruiting
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D.; Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 67 non-industry phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's planned 20 months is below that.

Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 6, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Hospital Universitario de Salamanca is now Recruiting
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Hospital Universitario de Salamanca is now Recruiting
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07394153
Lead sponsor
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
Collaborators
Swedish Orphan Biovitrum, MFAR Clinical Research S.L.
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Apr 15, 2026
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

A Responsible Person Designated by the sponsor, M.D., PhD.
Contact
investigacio@mfar.net
0034934344412
GEMFIN Secretary
Contact
secretaria@gemfin.org
0034934344412
Francisca Ferrer Marín, M.D.; Ph.D.
study chair · Fundación Jimenez Díaz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion